CAP/ASCO Issues New Guidelines to Improve IHC-based ER/PgR Analysis in Breast Cancer

CAP and ASCO issued new guidelines to improve accuracy of immunohistochemistry-based ER and PgR testing in breast cancer. The groups estimate that between 10 percent and 20 percent of IHC test results throughout the world may be inaccurate, yielding false-positive or false-negative results.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.